Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LabCorp's Orchid buy finally approved as it agrees to sell off paternity testing business

This article was originally published in Clinica

Executive Summary

Laboratory Corporation of America's (LabCorp's) acquisition of DNA testing specialist Orchid Cellmark has finally got the go-ahead from US antitrust authorities, after the firm agreed to divest Orchid's government paternity business. The $85.4m deal, which was announced in April (www.clinica.co.uk, 7 April 2011), has now been approved by the US Federal Trade Commission. LabCorp had extended the tender offer period 10 times as it tried to come to an agreement with the commission. The firm has already agreed to sell Orchid's government paternity testing business to privately-held DNA paternity testing specialist DNA Diagnostics Center once the transaction has closed. Dayton, Ohio-based Orchid also offers commercial paternity testing and forensic DNA testing. As well as the US, it also has labs in the UK and Canada.

You may also be interested in...



What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

EuroPCR: Medtronic's drug-coated balloon keeps rising

A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.

Topics

UsernamePublicRestriction

Register

MT098283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel